Updates in T cell Lymphoma Mary Jo Lechowicz August 2014 Disclosures - - PDF document

▶
updates in t cell lymphoma
SMART_READER_LITE
LIVE PREVIEW

Updates in T cell Lymphoma Mary Jo Lechowicz August 2014 Disclosures - - PDF document

Dec 01, 2023 158 likes •329 views

8/6/2014 Winship Cancer Institute of Emory University Updates in T cell Lymphoma Mary Jo Lechowicz August 2014 Disclosures Consulting fees from: Allos, Celgene, Millennium, and Seattle Genetics 1 8/6/2014 Objectives Update current

slide-1
SLIDE 1

8/6/2014 1 Winship Cancer Institute of Emory University

Updates in T cell Lymphoma

Mary Jo Lechowicz August 2014

Disclosures

  • Consulting fees from:

– Allos, Celgene, Millennium, and Seattle Genetics

slide-2
SLIDE 2

8/6/2014 2

Objectives

  • Update current care for patients with Peripheral T

cell Non Hodgkin lymphomas (PTCL) upfront treatment

  • Update current care for patients with

relapsed/refractory PTCL

  • Describe the experience and treatment of Breast

Implant Associated Alk positive t cell lymphoma Fig 1. Distribution of 1,314 cases by consensus diagnosis

International T‐Cell Lymphoma Project, J Clin Oncol; 26:4124‐4130 2008

slide-3
SLIDE 3

8/6/2014 3

Upfront treatment for PTCL

  • No Standard of Care!
  • Most common approach is CHOP/CHOP like
  • NCCN guidelines suggest

– Clinical trial – CHOP‐14 or 21 – CHOP followed by IVE or ICE – CHOEP – Dose adjusted EPOCH – HyperCVAD

Ongoing trials in Upfront Setting

Slide by S Horwitz 2014 PanPacific Lymphoma

slide-4
SLIDE 4

8/6/2014 4

A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating with Pralatrexate (P) as Front Line Therapy PTCL

Ranjana H. Advani, Stephen M. Ansell, Mary J. Lechowicz, Anne

  • W. Beaven, Fausto R. Loberiza Jr, Kenneth R. Carson, Andrew M.

Evens, Francine M. Foss, Steven M. Horwitz, Barbara Pro, Lauren Pinter‐Brown,Sonali M. Smith, Andrei R. Shustov, Kerry J. Savage and Julie M. Vose

  • Preliminary Results from the T‐ Cell Consortium Trial
  • ASH 2013 Adapted from Advani R et al. ASH abstract 3044.
  • Blood. 2013;122(21 suppl)

Background

Peripheral T‐cell lymphomas (PTCL) are a heterogeneous group of non‐Hodgkin's lymphomas (NHL) characterized by poor treatment outcomes with conventional chemotherapy, including CHOP [complete remission (CR) ~40%].

  • Retrospective studies suggest that the incorporation of

etoposide into chemotherapy regimens may improve

  • utcomes compared to CHOP.
  • In contrast, anthracyclines appear to have a limited role in

PTCL, largely attributed to p‐glycoprotein related

  • resistance. Pralatrexate was the first drug approved for

patients (pts) with relapsed PTCL, providing a rationale to evaluate it in the front‐line setting.

slide-5
SLIDE 5

8/6/2014 5

Methods

  • Eligible histologies included, PTCL‐NOS, AILT, ALCL (ALK

positive pts only allowed if IPI ≥ 3).

  • Cycle A: CEOP

‐ Cyclophosphamide 750 mg/m2 IV d1 ‐ Etoposide 100 mg/m2 IV d1‐3 ‐ Vincristine 2 mg IV day 1 ‐ Prednisone 100 mg/day X 5

  • Alternating Cycle B: Pralatrexate (P)

‐ 30 mg/m2 IV d 15, 22 and 29 (with vitamin B12 and folate supplementation)

  • Growth factors were used to support both cycles of therapy.
slide-6
SLIDE 6

8/6/2014 6

Conclusions

CR rate at end of therapy suggests the regimen is useful per study design.

  • Primary statistical aim of improving CR from 40‐60% not met.
  • Estimated 1 and 2 year PFS are 50% and 34% respectively.

‐ Age < 60 y, a low IPI score, achieving a CR and consolidation with ASCT were statistically significant for better PFS.

  • Estimated 1 and 2 year OS is 64%.

‐ Lack of B symptoms, low IPI score, achieving a CR and consolidation with ASCT were factors statistically significant for OS

  • Longer follow up is needed to assess the impact on the secondary
  • bjectives of EFS and OS

with this regimen.

  • 15 pts received ASCT with a younger median age (59 versus 68y) than those

who did not.

  • Defining optimal front line therapy in PTCL continues to be a challenge and

an unmet need.

slide-7
SLIDE 7

8/6/2014 7

Objectives

  • Update current care for patients with Peripheral T

cell Non Hodgkin lymphomas (PTCL) upfront treatment

  • Update current care for patients with

relapsed/refractory PTCL

  • Describe the experience and treatment of Breast

Implant Associated Alk positive t cell lymphoma

FDA approves Belinostat to treat rare, aggressive form of non‐ Hodgkin lymphoma

  • The FDA granted accelerated approval to Folotyn

(pralatrexate) in 2009 for use in patients with relapsed or refractory PTCL and Istodax (romidepsin) in 2011 for the treatment of PTCL in patients who received at least one prior therapy

  • July 2014 from treatment of 129 patients study
  • The Belief trials O’Connor OA et al. ASCO

2013;Abstract 8507

slide-8
SLIDE 8

8/6/2014 8

Background

 Study objective: To assess the safety and efficacy of

single-agent belinostat for patients with relapsed or refractory PTCL.

 Currently approved therapies for relapsed or refractory

PTCL have overall response rates of 25% to 29% (JCO 2011;29(9):1182-9; JCO 2012;30(6):631-6).

 Previously, a Phase II CLN-6 trial demonstrated that

belinostat monotherapy yielded an overall response rate

  • f 25% in relapsed/refractory PTCL (Proc ASH

2009;Abstract 920). – Belinostat was well tolerated, with the most common toxicities being Grade 1/2 gastrointestinal and constitutional side effects.

O’Connor OA et al. Proc ASCO 2013;Abstract 8507.

Eligibility (n = 129) Relapsed or refractory PTCL* ≥1 prior systemic therapy Platelet counts ≥50,000/uL No prior HDACi therapy No relapse within 100 days of autologous or allogeneic bone marrow transplant

* Confirmed by central pathology review (CPRG)

  • Primary endpoint: Objective response rate (ORR)
  • Secondary endpoints include: Safety, time to response, progression-free

and overall survival and duration of response

  • Exploratory analyses were conducted to determine response by PTCL

subtypes

Belinostat 1,000 mg/m2 (IV), d1-5 q3wk

Phase II BELIEF Trial Design

O’Connor OA et al. Proc ASCO 2013;Abstract 8507.

slide-9
SLIDE 9

8/6/2014 9

Response rate n = 120 ORR 26% Complete response (CR) 11% Partial response (PR) 15% Stable disease 15% Progressive disease 40% Not evaluable* 19%

Response by Central Review

* Prior to first radiologic assessment due to death (n = 7); clinical progression (n = 10); patient withdrawal (n = 5); lost to follow-up (n = 1) O’Connor OA et al. Proc ASCO 2013;Abstract 8507.

Characteristic Response rate Bone marrow involvement (n = 120) No (n = 65) 31% Yes (n = 35) 23% Indeterminate (n = 8) 25% Not assessed (n = 12) 8% Platelet counts (n = 120) ≥100,000/uL (n = 100) 28% <100,000/uL (n = 20) 15%

Response Rates According to Disease Characteristics

O’Connor OA et al. Proc ASCO 2013;Abstract 8507.

slide-10
SLIDE 10

8/6/2014 10

Diagnosis ORR PTCL-NOS (n = 77) 23% AITL (n = 22) 46% ALCL, ALK-negative (n = 13) 15% ALCL, ALK-positive (n = 2) 0% Enteropathy-associated TCL (n = 2) 0% Extranodal NK/TCL, nasal type (n = 2) 50% Hepatosplenic TCL (n = 2) 0%

Response Rates by CPRG Lymphoma Diagnosis

PTCL-NOS = PTCL-not otherwise specified; ALCL = angioimmunoblastic T-cell lymphoma; TCL = T-cell lymphoma O’Connor OA et al. Proc ASCO 2013;Abstract 8507.

Outcome All patients (n = 120) Baseline platelet counts ≥100,000/uL (n = 100) <100,000/uL (n = 20) ORR by CPRG 25.8% 28.0% 15.0% Median DoR 13.6 months 13.6 months 4.1 months Median PFS 1.6 months 1.8 months 1.3 months Median OS 7.9 months 9.2 months 4.3 months Median TTR 5.6 weeks 5.6 weeks 6.4 weeks

DoR = duration of response; PFS = progression-free survival; OS = overall survival; TTR = time to response

Clinical Outcomes

O’Connor OA et al. Proc ASCO 2013;Abstract 8507.

slide-11
SLIDE 11

8/6/2014 11

Event All patients (n = 129) Baseline platelet counts ≥100,000/uL (n = 105) <100,000/uL (n = 24) Thrombocytopenia 15% 6% 54% Neutropenia 13% 10% 25% Leukopenia 13% 9% 29% Anemia 12% 8% 29% Dyspnea 6% Not reported Pneumonia 6% Not reported Febrile neutropenia 5% Not reported Fatigue 5% Not reported Hypokalemia 4% Not reported

Select Grade ≥3 Adverse Events

O’Connor OA et al. Proc ASCO 2013;Abstract 8507.

Objectives

  • Update current care for patients with Peripheral T

cell Non Hodgkin lymphomas (PTCL) upfront treatment

  • Update current care for patients with

relapsed/refractory PTCL

  • Describe the experience and treatment of Breast

Implant Associated Alk positive t cell lymphoma

slide-12
SLIDE 12

8/6/2014 12 Breast Implant Associated Anaplastic Large Cell Lymphoma

  • First Case 1997 Keech and Creech
  • FDA following these cases
  • One lymphoma that surgical treatment alone

may be indicated?

slide-13
SLIDE 13

8/6/2014 13

slide-14
SLIDE 14

8/6/2014 14

Therapy Chosen

slide-15
SLIDE 15

8/6/2014 15

Conclusions

  • Ongoing research and monitoring needed
  • Most confined to fibrous capsule and have

good prognosis

  • Proper management may be capsulectomy

and implant removal

  • Patient presentation with a mass justifies

more aggressive therapy in addition to implant removal

Acknowledgements

  • The patients and their families
  • The Organizers
  • The Lymphoma Team at Winship

Cancer Institute at Emory University

  • All my co-T cell lymphoma

colleagues for all their guidance and support

slide-16
SLIDE 16

8/6/2014 16

Questions?